Login to Your Account



Vertex forecasts bright 2015, with expanded Kalydeco growth

By Michael Fitzhugh
Staff Writer

Monday, January 12, 2015

Vertex Pharmaceuticals Inc. said it expects 3,700 people with cystic fibrosis to be eligible to receive its therapy for the genetic disease, Kalydeco (ivacaftor), by end of 2015, supporting continued growth of the drug's global sales.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription